Anti-Aging from the Inside: HRT's Role in Longevity

By Dr. Farhan Abdullah, DO | Medical Director, Magnolia Functional Wellness | Southlake, TX

A patient asked me a question last spring that I'm still chewing on. She was 54, roughly three years past her final period, and she had just spent close to four thousand dollars on a skincare regimen she found through an ad on her phone. "Why does my face still look tired?" she wanted to know. I gave her the honest answer, which wasn't the one she came in for. She was treating the outside of something that begins on the inside. Her estradiol had been sitting near zero for three years. Skin is downstream of that. So is bone. So is muscle mass, blood vessel flexibility, and sleep quality, and sleep quietly multiplies everything else.

That conversation is a decent summary of why I do this work. I'm an internal medicine physician, and I still take care of hospitalized patients here in the Dallas area, which means I regularly see the far end of what happens when a decade of unaddressed physiology finally comes due. At Magnolia Functional Wellness in Southlake, I get to work at the other end of that same timeline. Before the hip fracture. Before the cardiac event. Before the slow slide into frailty that most people accept as simply what happens.

Hormone replacement therapy usually gets discussed as a symptom drug. Hot flashes, night sweats, irritability, the 3 a.m. wake-up. Those are real, and they're often what brings a woman into my office. But the more interesting question, and the one with better evidence behind it than most patients realize, is what estrogen does to the trajectory of aging itself.

What Actually Leaves When Estrogen Leaves

Estrogen is not a reproductive hormone that happens to have effects elsewhere. It's a systemic signaling molecule, and its receptors show up in bone, brain, vascular endothelium, skin, skeletal muscle, and the gut lining. When ovarian output falls off, every one of those tissues receives a new and less favorable set of instructions at roughly the same time.

Bone is the clearest example. Women lose bone mineral density fastest in the first five to seven years after menopause, and that acceleration isn't gradual. It's a step change. Skin collagen follows a similar curve. The often-cited figure is that women lose about a third of their dermal collagen in the first five years postmenopause, which is why the skin change so many of my patients describe feels less like slow aging and more like something switched off.

Then there's the vascular side, which is where the longevity conversation actually lives. Estrogen supports nitric oxide production in the endothelium, the single-cell layer lining every blood vessel you have. Less estrogen means less endothelial flexibility, which contributes to the rise in blood pressure and arterial stiffness that shows up in so many women in their mid-fifties who were fine at 48.

Body composition shifts too. Fat redistributes from the hips and thighs toward the abdomen, and visceral fat is metabolically noisy in a way subcutaneous fat isn't. It drives insulin resistance and low-grade inflammation. Meanwhile muscle protein synthesis becomes less efficient, so the same amount of training buys less than it used to.

None of this is a moral failing or a willpower problem, which is what a lot of women have been quietly told. It's endocrinology.

The Mortality Data Almost Nobody Quotes Correctly

Here's where I have to be careful, because this topic has been mangled in both directions for twenty years.

In 2002, the Women's Health Initiative published early results that were reported as showing hormone therapy caused breast cancer and heart disease. Prescriptions fell off a cliff. An entire generation of physicians was trained to be afraid of estrogen, and an entire generation of women went untreated. I trained in that shadow myself.

What got far less attention was the long-term follow-up. In 2017, a team led by JoAnn Manson published an analysis in JAMA covering 18 years of cumulative follow-up across both WHI hormone therapy trials, involving more than 27,000 women. The finding: hormone therapy was not associated with any increase in all-cause mortality, cardiovascular mortality, or total cancer mortality. The hazard ratio for all-cause death hovered essentially at 1.0 in both the estrogen-plus-progestin arm and the estrogen-alone arm.

That is not the same as saying hormone therapy extends life. It doesn't say that, and I won't pretend it does. What it says is that the central fear driving two decades of clinical avoidance did not hold up when researchers followed these women to the end. That's a meaningful correction, and most women I meet have never heard it.

What I tell my patients is this: the WHI enrolled a population with an average age of 63, many of them more than a decade past menopause, and it used oral conjugated equine estrogen with medroxyprogesterone acetate. Those details turn out to matter enormously.

Timing Is Most of the Argument

The idea that when you start matters more than whether you start is now reasonably well supported, and it changed how I practice.

The ELITE trial, led by Howard Hodis and published in the New England Journal of Medicine in 2016, was built specifically to test this. Researchers randomized postmenopausal women to oral estradiol or placebo, then split them by how far out from menopause they were. In women less than six years postmenopause, estradiol slowed the progression of carotid artery intima-media thickness, a direct structural measure of early atherosclerosis. In women more than ten years out, it did nothing. Same drug. Same dose. Completely different vascular result depending on when it started.

A Cochrane systematic review by Boardman and colleagues, covering 19 randomized trials and over 40,000 women, found something consistent with that. Women who began hormone therapy within ten years of menopause had lower all-cause mortality and lower coronary heart disease events than those on placebo. Women who started later did not see that benefit, and carried a higher stroke risk.

So the window is real, and it's roughly the decade after your final period. That's an uncomfortable thing to explain to a 68-year-old who's been told for twenty years that estrogen would kill her, because the honest answer is that the vascular opportunity has largely passed. We can still help her with symptoms, bone protection, and genitourinary health. The arterial benefit is a different conversation.

Bone, Muscle, and What Actually Ends Independence

If you want to think about longevity in practical terms, stop thinking about lifespan for a minute and think about the events that end an independent life. In my hospital work, the most common one by a wide margin is a hip fracture in an older woman.

The numbers on that are sobering, and they don't get repeated enough. A substantial fraction of women who fracture a hip never return to their prior level of function, and one-year mortality after hip fracture in older adults runs high enough that any internist will tell you it's a sentinel event, not an orthopedic inconvenience. Hormone therapy remains one of the few interventions with randomized trial evidence for reducing fracture risk in postmenopausal women, and unlike most bone drugs, it wasn't prescribed for that reason in the trials where it showed up. It reduced fractures as a secondary finding.

Muscle matters just as much and gets discussed less. Sarcopenia, the age-related loss of muscle mass and strength, is what turns a stumble into a fall and a fall into a fracture. Estrogen and testosterone both play a role in maintaining muscle in women, and yes, women make and need testosterone. It's the hormone I find most often ignored in women's panels, and low levels frequently track with the fatigue, flat mood, and loss of drive that get written off as stress.

I want to be direct about something here. Hormones are not a substitute for resistance training and protein intake. They make training work better. A patient of mine who started lifting three days a week at 56 got more out of the next two years than hormone therapy alone would ever have given her. The hormones set the conditions. She did the work. If you want the honest version of a longevity plan, it looks like sleep, strength training, protein, cardiovascular fitness, and hormonal support that makes all four of those more achievable.

How We Actually Approach This at Magnolia

The current 2022 position statement from The North American Menopause Society lands about where I do clinically. For healthy women under 60 or within ten years of menopause, and without contraindications, the benefit-to-risk profile of hormone therapy is favorable for treating vasomotor symptoms and for preventing bone loss. Beyond that window, the calculation shifts and has to be individualized.

What that looks like in practice at our Southlake clinic is a full panel, not a single number. Estradiol, FSH, total and free testosterone, SHBG, thyroid, a metabolic panel, lipids including ApoB when it's warranted, and inflammatory markers. Then a real conversation about personal and family history, because a woman with a first-degree relative with breast cancer or a personal history of clotting needs a different discussion than one without.

Route of delivery matters. Transdermal estradiol avoids first-pass hepatic metabolism, which is relevant to clotting risk in a way oral formulations aren't. If a uterus is present, progesterone is not optional, it's endometrial protection. And dosing is not set-and-forget. We recheck, we adjust, and we track symptoms alongside labs, because the labs alone will lie to you.

I also tell patients what hormone therapy won't do. It won't offset a diet built on ultra-processed food. It won't compensate for five hours of sleep. It isn't a longevity guarantee, and anyone selling it that way is overselling. What it can do is remove a headwind that a lot of women have been fighting without knowing it was there. You can read more about how we structure care on our women's hormone replacement therapy page, and about how hormones fit into the broader picture on our longevity medicine page.

The patient I mentioned at the start is doing well, by the way. We started her on transdermal estradiol with oral progesterone about fourteen months ago, added a small amount of testosterone after her second panel, and she joined a strength class near Southlake Town Square that she now refuses to miss. Her skin did improve, which she noticed first. Her DEXA scan two months ago was the part I cared about more. If you're somewhere in that perimenopausal or early postmenopausal window and wondering whether the fatigue and the changing body are just what happens now, that's a question worth asking a physician who will actually run the labs and look at the whole picture rather than hand you a cream.